Quick Answer
Galera Therapeutics, Inc. reported Earnings Per Share Diluted of $0.64 per share for the year ending 2025.
- Galera Therapeutics, Inc. showed an increase of +288.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.88 (loss) per share | Q3 2021: $0.86 (loss) per share | Q1 2022: $0.58 (loss) per share | Q2 2022: $0.54 (loss) per share | Q3 2022: $0.60 (loss) per share | Q1 2023: $0.50 (loss) per share | Q2 2023: $0.48 (loss) per share | Q3 2023: $0.33 (loss) per share | Q1 2024: $0.08 (loss) per share | Q2 2024: $0.07 (loss) per share | Q3 2024: $0.10 (loss) per share | Q1 2025: $0.01 (loss) per share | Q2 2025: $0.00 per share | Q3 2025: $0.01 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), Galera Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 148.1%.
- Historical annual values: Fiscal year 2025: $0.64 per share | Fiscal year 2024: $0.34 (loss) per share | Fiscal year 2023: $1.33 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: